Background
==========

The aim of the present report is to address the importance of studying non-communicable diseases (NCDs) and their relationship to aging in a systems approach. Understanding the complexity and interrelation of risk factors and disease networks requires the biologic sample collection, detailed and comprehensive phenotyping, and broad risk factor data. We present the international progress made in establishing large population-based biobank cohorts with the explicit aim to investigate non-communicable disease (NCD) etiology longitudinally. We point to the current inadequacy and the critical need to invest substantial research funding into NCD research in low and middle income countries in which the rise of NCDs converges with the high prevalence of infectious diseases. We discuss the relevance of studying pathophysiologic mechanisms linking different age-related NCDs and the aging process. We also highlight recent examples of phenome approaches. Finally, we point out striking pleiotropic findings of NCD phenotypic traits and genome-wide associations (GWAS) which clearly signpost an on-going paradigm shift in NCD research and underscore the potential of agnostic, complex data, systemic and multi-levelled methodologies leading to new understanding of chronic disease etiology.

International trend for prospective large-sized biobank cohorts
---------------------------------------------------------------

NCDs convey more than 50% of the global burden of disease and are challenging the health of populations worldwide. In high income countries (HICs), the epidemic of NCDs has been recognizably the major public health challenge over the last decades \[[@B1]\]. For this reason several HICs have increased their research efforts and invested substantial funding in extremely large population-based prospective cohort studies (with samples sizes over 200′000). These mega-cohorts (Table [1](#T1){ref-type="table"}; see also <http://www.p3g.org>) apply detailed phenotype descriptions over time, exhaustive temporal assessment of personal and environmental information and include high quality biologic sample collections for future genetic and functional analyses \[[@B2]\]. Prospective biobanking represents a powerful tool for establishing causal relationships as the time-order of sampling and of phenotyping is generally clear. Both hypothesis-driven as well as agnostic research can be conducted. Biologic samples in research can be used to test genetic determinants (e.g. genetic variants of N-Acetyltransferases, *NAT1* and *NAT2*) potentially mediating susceptibility (e.g. increased cancer risk), to discover or validate biomarkers as land marks of mechanisms (e.g. acetylation of aromatic and heterocyclic amines), or to sense and estimate individual environmental exposures (e.g. variable toxicity of carcinogens). Additional applications are expected to increase in the future. General good practices for biobanking in research have been defined (e.g. <http://www.ieaweb.org> for epidemiologic settings). An increasing need for biologic samples has therefore been the driving force to establish biobank collections in various clinical and observational settings \[[@B3]\]. A well-known example is the UK biobank, collecting blood, saliva and urine of more than 500′000 participants. Questionnaire and measurement data were collected at baseline and follow-up examinations are performed in subsets of the cohort \[[@B4]\]. There are also efforts of similar dimension in low and middle income countries (LMIC) such as the Chinese Biobank Study \[Kadoorie Study of Chronic Disease in China (KSCDC)\]. This project is a blood-based health database aiming at collecting genetic, environmental and lifestyle data on 510′000 adults aged 30--79 years to understand the causes, risk factors, pathogenesis, prevalence patterns and trends of major infectious and NCDs \[[@B5]\]. The establishment, maintenance and repeated collection of participant data require a substantial long-term investment of research funds. Critical voices point to the tremendous costs and to the methodological challenges to keep bias low over a long follow-up time in a multi-centric study design. But the scientific utility of such large longitudinal datasets is undisputed \[[@B6],[@B7]\]. Understanding the genetic, molecular and mechanistic background of interdependence between NCDs, comorbidities and risk factors during the aging process is a research priority for public health. Sufficiently powered cohorts and biobanks with broad, yet refined characterization of participants for risk factors and health phenotypes are a *conditio sine qua non* to achieve this goal.

###### 

Selection of ongoing mega-cohort studies in adults

  **Web site**                                                                                  **Cohort study**                                       **Country**         **Country size**   **Focus**                                                                                                             **Sample size** **Baseline**   **Biologic samples**
  --------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------- ----------------- -------------- --------------------------------
  \--                                                                                           CONOR/HUNT                                             Norway              4,9 Mio            Common disease etiology                                                                                                       185′000 1994-1995      Blood
  <http://www.millionwomenstudy.org/>                                                           Million women study                                    United Kingdom      62,3 Mio           Women's health                                                                                                              1′300′000 1996 - 2001    Blood, saliva, in a sub-sample
  <http://epic.iarc.fr/>                                                                        EPIC                                                   Europe              738,2 Mio          Nutrition, life style and cancer other diseases                                                                               520′000 1997           Blood
  \--                                                                                           Mexico city prospective study                          Mexico              117,4 Mio          Major determinants of morbidity and premature mortality                                                                       150′000 1998-2004      Blood
  <http://www.decode.com/research/>                                                             deCODE                                                 Iceland             0.4 Mio            Research company                                                                                                              200′000 2000           Various
  <http://www.milleniumcohort.org/>                                                             Millennium                                             USA                 313,3 Mio          US military family cohort                                                                                                     150′000 2001           Not specified
  <http://www.geenivaramu.ee/en/>                                                               Estonian biobank                                       Estonia             1.3 Mio            Biologic resource                                                                                                              50′000 2002           Blood
  <http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/Guangzhou/index.aspx>   Guanghzou Biobank Cohort study                         China               1339,7 Mio         Genetic, lifestyle, occupational and environmental factors, and life course Causes of the common chronic diseases              40′000 2003           Blood, urine
  <http://www.ckbiobank.org/>                                                                   China Kandoorie Biobank                                China               1339,7 Mio         Chronic disease etiology, complex interplay of lifestyle, environmental, and genetic susceptibility                           500′000 2004-2008      Blood
  <http://www.phri.ca/pure/index.html>                                                          PURE                                                   Several countries   3223,7 Mio         Maladaptation to urbanization and cardiovascular health                                                                       120′000 2006           Blood
  <http://www.ukbiobank.ac.uk/>                                                                 UK biobank                                             United Kingdom      62,3 Mio           Common disease etiology                                                                                                       500′000 2007 - 2010    Blood, saliva, urine
  <http://www.lifelines.net/>                                                                   LifeLines                                              The Netherlands     16,8 Mio           causes and prognosis of burden of disease, co-determinants, rather than comorbidity, family study                             165′000 2007           Blood, urine
  <https://www.etude-nutrinet-sante.fr/fr/common/login.aspx>                                    Nutrinet Santé                                         France              65,4 Mio           Nutrition and health                                                                                                          500′000 2009           Blood, urine
  <http://www.partnershipfortomorrow.ca/>                                                       The Canadian Partnership for Tomorrow Project (CPTP)   Canada              34,4 Mio           Cancer and chronic disease etiology                                                                                           300′000 2009           Blood
  <http://lifegene.ki.se/>                                                                      Life gene                                              Sweden              9,4 Mio            Nealth and lifestyle                                                                                                          500′000 2011           Blood, urine
  <http://www.constances.fr>                                                                    CONSTANCES                                             France              65,4 Mio           Biologic and research resource                                                                                                500′000 2011           Blood
  <http://www.nationale-kohorte.de/index_en.html>                                               German national cohort                                 Germany             81,8 Mio           Common disease etiology                                                                                                       200′000 2012           Blood

Listed by date of baseline examination start.

Discussion
==========

Biobank cohorts and chronic disease research in low and middle income countries (LMIC)
--------------------------------------------------------------------------------------

Research on NCDs almost exclusively relies on cohort data and associated biological samples collected in HICs. The recent update of global burden of disease estimates marks a shift from communicable towards non-communicable diseases and from life years lost due to premature death to increased number of years lived with chronic diseases and disabilities in LMICs \[[@B1],[@B8]\]. Though regionally heterogeneous, the LMICs show a persistently high proportion of infectious diseases in addition to a recent increase in prevalence of NCDs such as ischemic heart disease, stroke and diabetes. This observed convergence of NCDs and communicable diseases causes a dual burden of disease \[[@B9]\] for which most LMICs not only lack adequate health system resources, but also research funds to address the regional and local public health challenges \[[@B10]\]. Though causal relationships of NCD etiology and preventive measures identified in population-based biobank cohort studies in HICs will most likely inform public health decisions in LMICs, it is obvious that repeating studies of established NCD risk factors in LMICs will be necessary for proper estimation of their contribution to the disease burden \[[@B11]\]. Much can be learned about effect modifiers and risk factors by paralleled establishment of biobank cohorts in different settings. From human genome variation studies we already know that many African populations harbour a larger degree of genetic variation \[[@B12]\]. Several examples of high quality cohort study efforts in LMIC have been undertaken \[[@B7]\] (Table [1](#T1){ref-type="table"}). For example, the prevalence of healthy lifestyle in patients with cardiovascular disease (n = 7519) was investigated in the PURE study, a large-scale epidemiological study that recruited \>140,000 individuals residing in in 17 low-, middle-, and high-income countries around the world, and revealed strong correlation of decreasing levels of healthy lifestyle with decreasing country income level \[[@B13]\]. The Guangzhou Biobank Cohort Study \[[@B14]\], combining the use of biomarkers and questionnaire data for investigation of NCDs health system use as well as NCDs etiology, is another excellent example of a regional population-based cohort study in a country transiting fast from low to high income settings, albeit with large social discrepancies. Such large scale biobank cohort studies in LMICs face numerous challenges including funding, political, cultural and religious issues, but they are imminently important to collect data and monitor the dynamics of changes in environmental, life style, societal and health parameters with the increasing trend of urbanization in these countries \[[@B7]\]. They also contribute importantly to increasing the global competitiveness of research in LMICs \[[@B15]\].

Phenome approach towards disease networks
-----------------------------------------

In aiming to improve understanding of NCD etiology refined phenotyping of specific health outcomes is a necessity. Clinical disease diagnosis based research is known to be challenged by phenotypic heterogeneity. As an example, asthma, an intermittent chronic respiratory disease can be defined as a clinical diagnosis of asthma, but it is known that there are important differences in etiology and mechanisms depending on age of asthma onset or the presence of atopy and allergies. GWAS findings clearly revealed that the locus 17q21 determined childhood and not adult onset asthma \[[@B16],[@B17]\]. Statistical clustering approaches applied to the multilayer disease characteristics of a large group of asthmatic patients identified four distinct asthma phenotype groups: active treated allergic childhood-onset asthma; active treated adult-onset asthma; inactive or mild untreated asthma differing by atopy status and age of asthma onset \[[@B18]\]. In general up to recently, genetic investigations of NCD determinants, especially in large-scale GWAS meta-analyses, reduced the phenotype studied to a clinical diagnostic entity, a fact that may contribute to the disappointingly low predictive power of common genetic disease variants identified to date \[[@B19]-[@B21]\]. The importance of precise phenotyping for identifying the genetic contribution to common disease has been stressed since the time point of completion of the human genome project \[[@B22]\]. Clearly this challenges meta-analyses of data from different medium-sized cohorts collected in non-harmonized ways. International efforts to develop harmonized phenotype definitions lead early on to the Human **Phenome** Project \[[@B22],[@B23]\]. Since the initiative call phenome based databases were established (e.g. bipolar disorder phenome \[[@B24]\]; epilepsy phenome/genome project \[[@B25]\]; mouse phenome \[[@B26]\]; human pathology centered phenomes on cardiomyopathy \[[@B27]\], deafness \[[@B28]\], cardiac conduction characteristics \[[@B29]\], human skeletal phenome \[[@B30]\]). Phenotypes forming the basis of the phenome approaches can refer to any characteristic or trait measureable in an organism. It can be as diverse as a morphologic, biochemical, physiological, electrical, behavioral, epigenetic trait and these measures show a large inter-individual variability. Recently phenome-based approaches proofed their usefulness in identifying context-dependent clinical reference values for white blood cell counts \[[@B31]\]. Other recent phenome approaches applied semantic web technologies to scan electronic health records comprising clinical and biologic medical data for identifying genotype-phenotype associations \[[@B32],[@B33]\]. The current applications of the phenome approaches illustrate well the broad definition of the "phenome" summarizing often a large collection of phenotypes. Refined phenome approaches must be expanded to the concept of disease networks \[[@B34],[@B35]\], the **Diseasome**. According to a European population-based survey 25% of the respondents of age older than 14 years reported the presence of more than one chronic condition \[[@B36]\]. A systematic evidence review reported prevalence ranges of multi-morbidity in elderly of 55% to 98% \[[@B37]\]. The identification and clustering of human disease etiologic factors was undertaken in a bioinformatic driven data-mining approach using MeSH annotation of MEDLINE-referenced articles and the authors produced the etiome profile for 863 diseases (available at <http://etiome.stanford.edu>) \[[@B38]\]. New analytical approaches open novel exploratory avenues of investigation supporting the paradigm shift towards systematic, multi-layered and more exhaustive phenotypic catalogs. Patient records from a 1.5 million large patient population were used to establish correlation links of 161 disorders with disease phenotypes allowing to estimate the genetic overlap within the disease network \[[@B39]\]. A comorbidity database, the human disease network, was established from the analysis of 30 Mio Medicare patient data linking diseases and comorbidities (available at <http://hudine.neu.edu/>) \[[@B40]\]. More recently, to better understand disease similarities independent research groups have explored the clustering of genome-phenome correlations on a large number of published phenotype -- gene associations \[[@B41]\], or the type 2 diabetes genetic loci \[[@B42]\] or the major histocompatibility complex class II surface receptor, HLA-DRB1 \[[@B43]\]. These reports clearly proof the huge potential of bioinformatics-driven data-mining methodologies to shape the diseasome by classification of disease phenotypes and molecular diseases pathways. Thus such public health relevant research will continue to steadily improve our understanding of the phenotypic overlap of different NCDs and their link to aging processes. These system approaches to disease must furthermore be paralleled by systems approaches to understand risk factors. The concept of the phenome has thus been supplemented by the concept of the **Exposome** which measures environmental exposure as internal intermediate phenotypes of exposed organisms \[[@B44]-[@B46]\] using metabolomic and proteomic methods for quantification of molecular traits.

Accelerated aging processes as a link to NCD comorbidity
--------------------------------------------------------

Given that NCDs are chronic the proportion of comorbidities or secondary NCDs increase with age. Beyond this play of chance, NCD risk factors are known to accelerate the aging process of various organs. Smoking and obesity are among the most consistent factors showing adverse effects on all features of aging. For example, smoking, a potent risk factor for cardiovascular and respiratory NCDs has been suggested to promote cellular senescence of the lung \[[@B47]\], to impair the immune response \[[@B48]\] and increase skin aging \[[@B49]\]. Likewise obesity, a major risk factor for cardiovascular NCDs has been associated with age-related disease of the CNS \[[@B50]\]. Telomere shortening, a marker of the aging process, is inversely associated with several risk factors of diabetes and mitochondrial function in diabetic patients compared to healthy controls \[[@B51]\]. Telomere length was positively correlated with good glycemic/lipid control and negatively correlated with adiposity and insulin resistance \[[@B51],[@B52]\]. Other NCD risk factors such as sun light or weight loss exhibit adverse effects on more restricted features of aging such as skin aging or osteoporosis (see Table [2](#T2){ref-type="table"} as illustrative example).

###### 

Risk factors of NCDs and aging

  **Risk factor studied**              **Disease or trait**       **Acclerated aging and impaired function**   **Reference**
  ------------------------------------ -------------------------- -------------------------------------------- ---------------
  Smoking                              Humoral immunity           Immune system aging                          \[[@B48]\]
                                       Inflammatory response      Immune system aging                          \[[@B53]\]
                                       Heart rate variabiltiy     Autnomous nervous system aging               \[[@B54]\]
                                       Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
                                       Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
                                       Elastosis of the neck      Skin aging                                   \[[@B57]\]
                                       Bone mineral density       Bone aging                                   \[[@B58]\]
  Obesity, BMI, high calorie intake,   Impaired immune response   Immune system aging                          \[[@B59]\]
  Waist-hip ratio, skin-folds,         CD8 Tcell activation       Immune system aging                          \[[@B59]\]
  Body weight                          Lipodystrophy              Adipocyte aging                              \[[@B60]\]
                                       Heart rate variabiltiy     Autnomous nervous system aging               \[[@B61]\]
                                       Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
                                       Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
                                       Alopecia                   Hair aging                                   \[[@B62]\]
                                       Bone mineral density       Bone aging                                   \[[@B58]\]
  Dyslipidemia                         Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
                                       Alopecia                   Hair aging                                   \[[@B62]\]
  History of diabetes                  Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
                                       Bone mineral density       Bone aging                                   \[[@B58]\]
  Hypertension,                        Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
  High resting pulse                   Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
                                       Osteoporosis               Bone aging                                   \[[@B63]\]
                                       Bone mineral density       Bone aging                                   \[[@B58]\]
  Other chronic diseases,              Immunosenescence           Immune system aging                          \[[@B64]\]
  Comorbidity                          Lipodystrophy              Adipocyte aging                              \[[@B65]\]
                                       Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
                                       Sacropenia                 Muscle aging                                 \[[@B66]\]
                                       Osteoporosis               Bone aging                                   \[[@B63]\]
  Medication intake                    Sacropenia                 Muscle aging                                 \[[@B66]\]
                                       Osteoporosis               Bone aging                                   \[[@B63]\]
  UV light/sun exposure                Alopecia                   Hair aging                                   \[[@B62]\]
  Low sun exposure                     Elastosis of the neck      Skin aging                                   \[[@B57]\]
                                       Sacropenia                 Muscle aging                                 \[[@B66]\]
  Health behaviours                    Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
  Low level of mental activity         Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
  Physical inactivity                  Sacropenia                 Muscle aging                                 \[[@B66]\]
                                       Osteoporosis               Bone aging                                   \[[@B63]\]
  Depression                           Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
  Poor diet                            Sacropenia                 Muscle aging                                 \[[@B66]\]
  Weight loss/no weight gain           Osteoporosis               Bone aging                                   \[[@B63]\]
  Low education                        Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]
                                       Atherosclerosis            Cardiovascular aging                         \[[@B56]\]
  Psychosocial factors                 Alzheimer                  Premature cognitive impairment, CNS aging    \[[@B55]\]

Content of table is illustrative, not exhaustive.

The natural history of aging is characterized by a diminished self-renewal capacity of the organism resulting in sclerodermatous changes of the skin, alopecia, osteoporosis, sarcopenia, muscle atrophy, generalized lipodystrophy, atherosclerosis, decreased elasticity of the vascular system, immunologic senescent changes such as decline in humoral immunity, T-cell functional dysregulation, innate and adaptive immune functions \[[@B48],[@B59],[@B64],[@B67]\]. Characteristic land marks of aging are also neurologic senescent changes of the central, peripheral and autonomic nervous system including limited neuronal loss, glial proliferation in the cortex and an overall brain weight decrease, degradation of sensory performance, decline in proprioception and somatosensory information processing and also reduced reactivity of the sympathetic and the parasympathetic nervous activity \[[@B68],[@B69]\]. It is likely that systemic approaches combining the focus on accelerated aging, NCDs, environmental and genetic risk factors will point to the underlying disease biology. Understanding how shared risk factors affect mechanisms common to NCDs and aging processes is important from a public health perspective to meet effective prevention programs.

Lessons learned from genetics on NCD clustering: pleiotropic gene variants
--------------------------------------------------------------------------

Despite ongoing debates about the limitation of GWAS findings from the predictive personalized medicine perspective, GWAS studies do not announce the end of complex disease genetics, but rather a promising first step. Completely novel genes expand our understanding of NCD pathology. A large number of GWAS loci have been consistently associated with one or multiple NCDs in independent populations (see Additional file [1](#S1){ref-type="supplementary-material"}; <http://www.genome.gov/gwastudies>). Evidence for pleiotropy of loci, genes and even specific SNPs suggests important mechanistic links between diseases and is of potential relevance to advance understanding the biology of NCD clusters, co-morbidities and aging processes. A recent meta-analysis of 372 GWAS on 105 unique age-related diseases revealed the clustering of genetic variants in ten significantly enriched chromosomal locations which contain genes involved in inflammation and cellular senescence \[[@B70]\]. Pleiotropy is defined as a genetic variant or a gene having an effect on multiple phenotypes. In Table [3](#T3){ref-type="table"}, we present an overview of specific SNPs likely to be pleiotropic. They were consistently associated with different forms of cancer (i.e. **rs401681**, *TERT*, *CLPTM1L*, 5p15.33 -- associated with lung, bladder, pancreatic cancer, melanoma and prostate-specific antigen levels) and of chronic inflammatory diseases (i.e. **rs11209026**, *IL23R*, 1p31.3 -- associated with Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriasis; **rs10488631**, *IRF5,TNPO3*, 7q32.1 -- associated with systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis and primary biliary cirrhosis; see Additional file [2](#S2){ref-type="supplementary-material"} for detailed summary of pleiotropic SNPs). This observed non-random clustering of NCD-linked traits and specific pleiotropic SNPs can be used to identify biologic mechanisms shared by different NCDs. In a recent study a method was presented to evaluate the pleiotropy among GWAS-identified SNPs and genes for common complex disease and traits; it reported that 17% of the GWAS genes and 4% of the GWAS SNPs showed evidence of pleiotropy \[[@B71]\]. Although pleiotropy had been suggested to be common to the genetic architecture of complex disease \[[@B72]\], only isolated cases of pleiotropy had been reported previously such as the links between *APOE* genotypes and dyslipidemia, coronary heart disease and Alzheimer\'s disease \[[@B73]\], and type 2 diabetes and prostate cancer (*TCF2 genotypes*) \[[@B74]\]. The genetic overlap between psoriasis, diabetes type 2 and Crohn's disease, three inflammatory diseases affecting distinct organs, was identified by combining evidence from linkage and GWAS data \[[@B75]\]. Recently antagonistic pleiotropic effects of genetic variants were evidenced conferring risk for one disease, diabetes type 1, and protection for another disease, inflammatory bowel disease \[[@B76]\].

###### 

Pleiotropic GWAS loci of NCDs

                         **Locus, gene**                         **dbSNP ID**  **NCD entity associated with SNP**                  **P-value**   **Risk allele frequency**   **PubMed ID**
  ------------------------------------------------------------- -------------- -------------------------------------------------- ------------- --------------------------- ---------------
                 **Cancer linked NCDs cluster**                                                                                                                             
                          5p15.33, TERT                           rs2736100    Glioma                                               2.00E-17               0.49                19578367
                                                                  rs2736100    Glioma                                               1.00E-14                NR                 21531791
                                                                  rs2736100    Glioma                                               7.00E-09                NR                 21827660
                                                                  rs2736100    Hematological and biochemical traits                 3.00E-08                0.4                20139978
                                                                  rs2736100    Idiopathic pulmonary fibrosis                        3.00E-08               0.41                18835860
                                                                  rs2736100    Lung adenocarcinoma                                  2.00E-22               0.39                20700438
                                                                  rs2736100    Lung adenocarcinoma                                  3.00E-11               0.39                20871597
                                                                  rs2736100    Lung cancer                                          1.00E-27               0.41                21725308
                                                                  rs2736100    Testicular germ cell cancer                          8.00E-15               0.49                20543847
                     5p15.33, TERT, CLPTM1L                        rs401681    Bladder cancer                                       5.00E-07               0.54                20972438
                                                                   rs401681    Lung cancer                                          8.00E-09                NR                 18978787
                                                                   rs401681    Melanoma                                             3.00E-08               0.46                21983787
                                                                   rs401681    Pancreatic cancer                                    7.00E-07               0.45                20101243
                                                                   rs401681    Serum prostate-specific antigen levels               1.00E-10               0.55                21160077
                       8q24.21, Intergenic                        rs6983267    Colorectal cancer                                    1.00E-14               0.49                17618284
                                                                  rs6983267    Colorectal cancer                                    7.00E-11               0.48                18372905
                                                                  rs6983267    Colorectal cancer                                    2.00E-08               0.34                21242260
                                                                  rs6983267    Prostate cancer                                      9.00E-13                0.5                17401363
                                                                  rs6983267    Prostate cancer                                      9.00E-13               0.49                18264097
                                                                  rs6983267    Prostate cancer                                      7.00E-12               0.53                18264096
                                                                  rs6983267    Prostate cancer                                      9.00E-06                NR                 21743057
                     9p21.3, CDKN2A, CDKN2B                       rs4977756    Glaucoma                                             1.00E-14                0.6                21532571
                                                                  rs4977756    Glioma                                               7.00E-15                0.6                19578367
           **Inflammatory trait linked NCDs cluster**                                                                                                                       
                          1p31.3, IL23R                           rs11209026   Ankylosing spondylitis                               2.00E-17               0.93                21743469
                                                                  rs11209026   Ankylosing spondylitis                               9.00E-14               0.94                20062062
                                                                  rs11209026   Crohn's disease                                      1.00E-64               0.93                21102463
                                                                  rs11209026   Crohn's disease                                      4.00E-21                NR                 22293688
                                                                  rs11209026   Crohn's disease                                      2.00E-18               0.92                17447842
                                                                  rs11209026   Inflammatory bowel disease                           4.00E-11               0.93                17068223
                                                                  rs11209026   Inflammatory bowel disease                           7.00E-11               0.94                18758464
                                                                  rs11209026   Psoriasis                                            7.00E-07                NR                 20953190
                                                                  rs11209026   Ulcerative colitis                                   5.00E-28               0.94                21297633
                                                                  rs11209026   Ulcerative colitis                                   3.00E-10                NR                 19915572
                                                                  rs11209026   Ulcerative colitis                                   1.00E-08               0.93                19122664
                         1p13.2, PTPN22                           rs2476601    Crohn's disease                                      1.00E-08                0.9                18587394
                                                                  rs2476601    Rheumatoid arthritis                                 9.00E-74                0.1                20453842
                                                                  rs2476601    Rheumatoid arthritis                                 2.00E-21                NR                 19503088
                                                                  rs2476601    Rheumatoid arthritis                                 2.00E-11                0.1                17804836
                                                                  rs2476601    Type 1 diabetes                                      9.00E-85                NR                 19430480
                                                                  rs2476601    Type 1 diabetes                                      2.00E-80               0.09                17554260
                                                                  rs2476601    Type 1 diabetes                                      1.00E-07               0.09                17632545
                                                                  rs2476601    Type 1 diabetes autoantibodies                       2.00E-111               NR                 21829393
                                                                  rs2476601    Vitiligo                                             1.00E-07                0.1                20410501
                       7q32.1, IRF5,TNPO3                         rs10488631   Primary biliary cirrhosis                            3.00E-10               0.11                20639880
                                                                  rs10488631   Primary biliary cirrhosis                            2.00E-07                NR                 19458352
                                                                  rs10488631   Rheumatoid arthritis                                 4.00E-11               0.11                20453842
                                                                  rs10488631   Systemic lupus erythematosus                         7.00E-18               0.11                21408207
                                                                  rs10488631   Systemic lupus erythematosus                         2.00E-11               0.12                18204098
                                                                  rs10488631   Systemic sclerosis                                   2.00E-13                NR                 20383147
                                                                  rs10488631   Systemic sclerosis                                   2.00E-10                NR                 21779181
                                                                  rs10488631   Systemic sclerosis                                   2.00E-07                NR                 21779181
                                                                  rs10488631   Systemic sclerosis                                   4.00E-07               0.09                21750679
                         18p11.21, PTPN2                          rs2542151    Crohn's disease                                      5.00E-17               0.15                18587394
                                                                  rs2542151    Crohn's disease                                      3.00E-08               0.18                17554261
                                                                  rs2542151    Crohn's disease                                      2.00E-07               0.16                17554300
                                                                  rs2542151    Type 1 diabetes                                      1.00E-14               0.16                17554260
                                                                  rs2542151    Type 1 diabetes                                      9.00E-08                NR                 18978792
                                                                  rs2542151    Type 1 diabetes autoantibodies                       4.00E-13                NR                 21829393
                         18p11.21, PTPN2                          rs1893217    Celiac disease                                       3.00E-10               0.17                20190752
                                                                  rs1893217    Celiac disease and Rheumatoid arthritis              5.00E-12                NR                 21383967
                                                                  rs1893217    Type 1 diabetes                                      4.00E-15                NR                 19430480
          **Cardiovascular trait linked NCDs cluster**                                                                                                                      
                          2p23.3, GCKR                            rs1260326    Cardiovascular disease risk factors                  2.00E-08                0.4                21943158
                                                                  rs1260326    Cholesterol, total                                   7.00E-27               0.41                20686565
                                                                  rs1260326    Chronic kidney disease                               3.00E-14               0.41                20383146
                                                                  rs1260326    C-reactive protein                                   5.00E-40                NR                 21300955
                                                                  rs1260326    Hematological and biochemical traits                 4.00E-09               0.44                20139978
                                                                  rs1260326    Hypertriglyceridemia                                 7.00E-09               0.41                20657596
                                                                  rs1260326    Liver enzyme levels (gamma-glutamyl transferase)     4.00E-13               0.38                22001757
                                                                  rs1260326    Metabolic traits                                     4.00E-10               0.35                19060910
                                                                  rs1260326    Platelet counts                                      9.00E-10                NR                 22139419
                                                                  rs1260326    Serum metabolites                                    3.00E-18                NR                 22286219
                                                                  rs1260326    Triglycerides                                        6.00E-133              0.41                20686565
                                                                  rs1260326    Triglycerides                                        2.00E-31               0.45                19060906
                                                                  rs1260326    Two-hour glucose challenge                           3.00E-10                NR                 20081857
                                                                  rs1260326    Waist circumference and related phenotypes           4.00E-08                NR                 18454146
                      11q12.2, FADS1, FADS2                        rs174547    HDL cholesterol                                      2.00E-12               0.33                19060906
                                                                   rs174547    Lipid metabolism phenotypes                          8.00E-262               NR                 22286219
                                                                   rs174547    Metabolic traits                                     9.00E-116              0.32                21886157
                                                                   rs174547    Phospholipid levels (plasma)                         4.00E-154               NR                 21829377
                                                                   rs174547    Phospholipid levels (plasma)                         3.00E-64                NR                 21829377
                                                                   rs174547    Resting heart rate                                   2.00E-09               0.33                20639392
                                                                   rs174547    Serum metabolites                                    7.00E-179               0.3                20037589
                                                                   rs174547    Triglycerides                                        2.00E-14               0.33                19060906
                         11q14.3, MTNR1B                          rs1387153    Fasting plasma glucose                               2.00E-36               0.29                19060909
                                                                  rs1387153    Glycated hemoglobin levels                           4.00E-11               0.28                20858683
                                                                  rs1387153    Metabolic syndrome (bivariate traits)                2.00E-09                NR                 21386085
                                                                  rs1387153    Metabolic syndrome (bivariate traits)                8.00E-09                NR                 21386085
                                                                  rs1387153    Type 2 diabetes                                      8.00E-15                NR                 20581827
                      12q24.12, ALDH2, BRAP                         rs671      Coronary heart disease                               2.00E-34               0.23                21971053
                                                                    rs671      Drinking behavior                                    4.00E-211              0.75                21372407
                                                                    rs671      Esophageal cancer                                    3.00E-24                NR                 19698717
                                                                    rs671      Hematological and biochemical traits                 7.00E-10               0.26                20139978
                                                                    rs671      Hematological and biochemical traits                 5.00E-09               0.26                20139978
                                                                    rs671      Intracranial aneurysm                                3.00E-06               0.75                22286173
                                                                    rs671      Triglycerides                                        2.00E-06                NR                 22171074
                           16q13, CETP                            rs3764261    Age-related macular degeneration                     7.00E-09               0.33                21665990
                                                                  rs3764261    Age-related macular degeneration                     7.00E-07               0.32                20385819
                                                                  rs3764261    Cholesterol, total                                   7.00E-14               0.32                20686565
                                                                  rs3764261    HDL cholesterol                                      2.00E-57               0.31                18193043
                                                                  rs3764261    HDL cholesterol                                      7.00E-29               0.28                19060910
                                                                  rs3764261    HDL cholesterol                                      3.00E-12                0.2                19359809
                                                                  rs3764261    HDL cholesterol                                       7E-380                0.32                20686565
                                                                  rs3764261    LDL cholesterol                                      9.00E-13               0.32                20686565
                                                                  rs3764261    Lipid metabolism phenotypes                          1.00E-36                NR                 22286219
                                                                  rs3764261    Metabolic syndrome                                   1.00E-48               0.36                20694148
                                                                  rs3764261    Metabolic syndrome                                   3.00E-13                NR                 21386085
                                                                  rs3764261    Triglycerides                                        1.00E-12               0.45                20686565
                                                                  rs3764261    Waist circumference                                  1.00E-27                NR                 18454146
                          19p13.2, LDLR                           rs6511720    Cardiovascular disease risk factors                  5.00E-11               0.11                21943158
                                                                  rs6511720    Carotid intima media thickness                       1.00E-07                NR                 21909108
                                                                  rs6511720    Cholesterol, total                                   7.00E-97               0.11                20686565
                                                                  rs6511720    LDL cholesterol                                      4.00E-117              0.11                20686565
                                                                  rs6511720    LDL cholesterol                                      2.00E-51                0.1                18193044
                                                                  rs6511720    LDL cholesterol                                      2.00E-26                0.1                19060906
                                                                  rs6511720    LDL cholesterol                                      4.00E-26                0.9                18193043
                                                                  rs6511720    Lp-PLA2 activity and mass                            3.00E-11                0.1                22003152
                      19q13.32, APOE, APOC1                       rs4420638    Alzheimer's disease                                  2.00E-44                NR                 17998437
                                                                  rs4420638    Alzheimer's disease                                  1.00E-39                NR                 17975299
                                                                  rs4420638    Alzheimer's disease (age of onset)                   1.00E-12                NR                 22005931
                                                                  rs4420638    Alzheimer's disease (late onset)                     1.00E-39                NR                 17474819
                                                                  rs4420638    Cholesterol, total                                   5.00E-111              0.17                20686565
                                                                  rs4420638    Cognitive decline                                    4.00E-27                NR                 22054870
                                                                  rs4420638    C-reactive protein                                   9.00E-139               NR                 21300955
                                                                  rs4420638    C-reactive protein                                   5.00E-27                NR                 19567438
                                                                  rs4420638    C-reactive protein                                   3.00E-07                0.9                21196492
                                                                  rs4420638    HDL cholesterol                                      4.00E-21               0.17                20686565
                                                                  rs4420638    LDL cholesterol                                      9.00E-147              0.17                20686565
                                                                  rs4420638    LDL cholesterol                                      1.00E-60                0.2                18193044
                                                                  rs4420638    LDL cholesterol                                      3.00E-43               0.18                18193043
                                                                  rs4420638    LDL cholesterol                                      2.00E-40               0.18                20864672
                                                                  rs4420638    LDL cholesterol                                      4.00E-27               0.16                19060906
                                                                  rs4420638    LDL cholesterol                                      1.00E-20               0.18                18262040
                                                                  rs4420638    LDL cholesterol                                      2.00E-07                NR                 18802019
                                                                  rs4420638    Lp-PLA2 activity and mass                            5.00E-30               0.84                22003152
                                                                  rs4420638    Lp-PLA2 activity and mass                            6.00E-24               0.16                20442857
                                                                  rs4420638    Longevity                                            2.00E-16               0.81                21740922
                                                                  rs4420638    Quantitative traits                                  3.00E-07               0.21                19197348
                                                                  rs4420638    Triglycerides                                        3.00E-13               0.22                17463246
   **Cardiovascular & inflammatory trait linked NCDs cluster**                                                                                                              
                         12q24.12, SH2B3                          rs3184504    Coronary heart disease                               6.00E-06               0.44                21378990
                                                                  rs3184504    Diastolic blood pressure                             4.00E-25               0.47                21909115
                                                                  rs3184504    Diastolic blood pressure                             3.00E-14               0.48                19430479
                                                                  rs3184504    Eosinophil counts                                    7.00E-19               0.38                19198610
                                                                  rs3184504    Rheumatoid arthritis                                 6.00E-06               0.51                20453842
                                                                  rs3184504    Systolic blood pressure                              5.00E-09               0.48                19430479
                                                                  rs3184504    Type 1 diabetes                                      3.00E-27                NR                 19430480
                                                                  rs3184504    Type 1 diabetes autoantibodies                       2.00E-38                NR                 21829393
                     12q24.12, SH2B3, ATXN2                        rs653178    Blood pressure                                       7.00E-20               0.59                21909110
                                                                   rs653178    Celiac disease                                       7.00E-21                0.5                20190752
                                                                   rs653178    Celiac disease                                       8.00E-08               0.48                18311140
                                                                   rs653178    Celiac disease and Rheumatoid arthritis              3.00E-19                NR                 21383967
                                                                   rs653178    Chronic kidney disease                               4.00E-11                0.5                20383146
                                                                   rs653178    Diastolic blood pressure                             3.00E-18               0.53                19430483
            **Skin pigmentation linked NCDs cluster**                                                                                                                       
                          11q14.3, TYR                            rs1393350    Blue vs. green eyes                                  3.00E-12               0.23                17952075
                                                                  rs1393350    Eye color                                            3.00E-09               0.27                20585627
                                                                  rs1393350    Melanoma                                             2.00E-14               0.27                19578364
                                                                  rs1393350    Melanoma                                             2.00E-13               0.28                21983787
                                                                  rs1393350    Skin sensitivity to sun                              2.00E-06               0.27                17952075
                                                                  rs1393350    Tanning                                              2.00E-13                NR                 19340012
                                                                  rs1393350    Vitiligo                                             2.00E-18               0.73                20410501
                          16q24.3, MC1R                           rs1805007    Basal cell carcinoma                                 4.00E-17               0.07                21700618
                                                                  rs1805007    Blond vs. brown hair color                           2.00E-13               0.08                17952075
                                                                  rs1805007    Freckles                                             1.00E-96               0.05                17952075
                                                                  rs1805007    Red vs non-red hair color                            2.00E-142               NR                 17952075
                                                                  rs1805007    Skin sensitivity to sun                              2.00E-55               0.06                17952075

A selection of GWAS identified pleiotropic SNPs implicated in more than one NCD entity are presented here. For a more complete list of pleiotropic loci see Additional file [1](#S1){ref-type="supplementary-material"}. Data has been downloaded (09 March 2012) from the online catalogue of published GWAS available at <http://www.genome.gov/gwastudies>.

NR, not reported.

Lp-PLA2, lipoprotein-associated Phospholipase A2.

LDLR, Low density lipoprotein receptor.

HDL, High density lipoprotein.

LDLR, Low density lipoprotein.

Methodological challenge of data mining and of complex systems analysis
-----------------------------------------------------------------------

The research community is facing unprecedented statistical, data mining and analytical challenges as the next steps ahead are complex interaction studies of genes, other --omics markers, lifestyle, and environment on the phenome. Standard statistical approaches using linear causal relationships have shown to be limited for reproducible association studies on complex phenotypes as well as for two-way interaction analyses. Researchers will need to adapt their current methods by implementing approaches that reflect more closely the dynamics of adaptive biologic systems by taking non-linear and non-proportional relationships into account. Methods of complex system science and chaos theory have been applied to various biologic systems \[[@B77]\] and have been proposed to be applied to human health behavioral changes for public health prevention aims \[[@B78]\]. Fractal dynamics in physiology have shown to be relevant to disease and aging \[[@B79]\], to biologic signals in general \[[@B80]\] and chaotic motifs have been investigated in dynamic behavior of gene regulatory networks \[[@B81]\]. To date we have only started to investigate disease clusters and pleiotropic risk effects in a systematic manner \[[@B82],[@B83]\]. Formal analytical concepts of disease similarities and shared gene networks have been proposed to guide future research for the identification of molecular evidence of comorbidities \[[@B84]\]. Recent novel data mining approaches to combine GWAS findings and phenome data have been proposed to achieve NCD disease gene discovery, phenotype classification \[[@B41]\] and phenome-wide association studies \[[@B85]\] or to improve disease diagnostic procedures \[[@B27],[@B86]\]. Other bioinfomatic approaches combining animal model data of human disease and mammalian phenotype ontologies databases seem to suggest that germline genetic variation might underlie the heterogeneity of comorbidities \[[@B87],[@B88]\].

Summary
=======

In the present report, we covered a wide range of aspects of importance to NCD research, including establishments and maintenance of large and systematic biobank cohorts from all parts of the world; implementation of broad and detailed phenotyping, as well as broad and detailed risk factor assessment, including aging characteristics; development of novel analytical methods for systemic analysis, addressing networks of diseases, or of personal and environmental risk factors, as well application of agnostic genomic analysis methods. In fact, to meet current and future public health challenges and to improve efficacy of prevention at the individual as well as at the population level, we need answers to the following questions \[[@B89]-[@B92]\]: Which are major pathophysiologic pathways mediating the clustering of NCDs? To what degree are biological mechanisms shared between NCDs and normal aging? Do modifiable NCD risk factors act through common mechanisms? Can persons susceptible to common NCD risk patterns and comorbidities be identified?

To address this type of questions with data providing adequate statistical power and using hypothesis driven and explorative as well as agnostic approaches, establishment and maintenance of carefully designed large and comprehensive population-based cohorts with prospective collection of biological samples are a key requirement. Efforts must be further intensified to collaborate across cohorts from different geographic regions in a harmonized fashion, a process already started with remarkable success in P3G \[[@B93]\]. Harmonized and exhaustive phenotype collection is a particular challenge and novel instruments as developed for standardized assessment of multiple chronic diseases etiology \[[@B94]\] must be implemented. The quality management of a sustainable long-term biobank importantly comprises next to legislative, ethical and financial aspects also guaranteed safety of samples, temperature monitoring, traceability and parsimonious use of sample aliquots. Quality management of biological sample collection is particularly important for cohort studies with multi-centric design.

Given that biobank cohorts serve to increase the wellbeing of future generations by indirectly promoting biomedical knowledge and public health, these activities require the development of normative procedures and defined governance \[[@B95],[@B96]\]. There are still issues left to be resolved, such as establishing large biobanks for investigation of future research questions conflicts with the well accepted and widely implemented personal informed consent \[[@B97]\]. In the light of biobanking's interest for present and future society, it might be considered a great good \[[@B95]\] and according discussions for a possibility of general non-personalized consent in politics and public are needed. This debate paper aimed to highlight the potential of biobank cohort research for complex disease etiology, a field of research that will allow improving health of populations as well as informing individuals on quality-of life increasing health decisions.
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